Today, patients with CNS diseases face real challenges. No curative therapeutic treatment exists and CNS drug discovery no longer appears to be effective in adressing this need.
Thinking outside the box is our DNA. We believe that the most effective way to give our customers the means to move forward their CNS drug discovery programs is to “crack” the brain, by directly measuring its [dys]functions as soon as they appear.
These objective measures, from which we have identified relevant biomarkers, provide you with an efficient and safe Drug Discovery process. We can help you select the most effective lead from the earliest phase, avoiding further time-consuming and costly trials.
Corinne Roucard, CEO, and Yann Roche, COO.